Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

Key Inclusion Criteria:

- Subject must weigh ≤ 125 kg and have a body mass index between 20 and 40 kg/m2

- Subject must be willing to be confined in the clinical research unit for the duration
of the study, up to 5 days

- If female, subject must not be pregnant or lactating, have a negative pregnancy test,
and agrees to sexual abstinence, or use of an appropriate birth control method from
screening through 30 days after study drug administration

- If male, subject agrees to sexual abstinence, is surgically sterile, or is using an
appropriate birth control method from screening through 30 days after study drug
administration

- Considered by the Investigator to be healthy or clinically stable with respect to
underlying renal impairment based on medical evaluation including vital signs, ECG
and laboratory test results

- Non-smoker, or smokes fewer than 10 cigarettes/day

Key Exclusion Criteria

- Uncontrolled medical condition (treated or untreated) considered to be clinically
significant by the Investigator

- Experienced an illness considered by the Investigator to be clinically significant
within 2 weeks of study drug administration

- Treatment with another investigational drug or device study within 30 days or 5
half-lives (whichever is longer) prior to screening

- Positive test for drugs of abuse and/or positive alcohol test at Screening or Day -1

- Donated or lost a significant volume of blood or plasma within 90 days prior to study
drug administration